Evidence map›Paper›PMID 27427921›Full record

Trial reportBone marrow transplantation2017

A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantation.

J Magenau, P Westervelt, S Khaled, J McGuirk, P Hari, M Eapen, P S Becker, B Parkin, T Braun, B Logan and 11 more

Open access · bronzeAbstract readClinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Bone marrow transplantation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 21 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 12 institutions in 2 countries.

J MagenauDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
P WesterveltWashington University, St. Louis, MO, USA.
S KhaledCity of Hope, Duarte, CA, USA.
J McGuirkUniversity of Kansas, Westwood, KS, USA.
P HariMedical College of Wisconsin, Milwaukee, WI, USA.
M EapenMedical College of Wisconsin, Milwaukee, WI, USA.
P S BeckerFred Hutchinson Cancer Research Center, Seattle, WA, USA.
B ParkinDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
T BraunDepartment of Biostatistics, University of Michigan, Ann Arbor, MI, USA.
B LoganDivision of Biostatistics, Medical College of Wisconsin, Milwaukee, WI, USA.
H WangDivision of Biostatistics, Medical College of Wisconsin, Milwaukee, WI, USA.
M JagasiaVanderbilt University, Nashville, TN, USA.
S D RowleyHackensack University Medical Center, Hackensack, NJ, USA.
D D H KimPrincess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
T SchechterHospital for Sick Children, Toronto, Ontario, Canada.
N FreyUniversity of Pennsylvania, Philadelphia, PA, USA.
B ScottFred Hutchinson Cancer Research Center, Seattle, WA, USA.
T ChurayDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
S LielandDepartment of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
S FormanCity of Hope, Duarte, CA, USA.
S MineishiUniversity of Alabama at Birmingham, Birmingham, AL, USA.
University of Michigan–Ann Arbor · USMedical College of Wisconsin · USFred Hutch Cancer Center · USUniversity of Kansas · USCity of Hope · USHackensack University Medical Center · USHospital for Sick Children · CAUniversity of Alabama at Birmingham · USUniversity of Pennsylvania · USUniversity of Toronto · CAVanderbilt University · USWashington University in St. Louis · US

Funding

Data Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2M
NCI NIH HHS U24 CA076518
6 · The paper itself

Abstract

Allogeneic hematopoietic cell transplantation (HCT) may produce long-term survival in AML after relapse or primary induction failure (PIF). However, outcomes of HCT performed for AML not in remission are historically poor given high relapse rates and transplant-related mortality. Preliminary studies suggest conditioning with clofarabine and myeloablative busulfan (CloBu4) may exert significant anti-leukemic effects without excessive toxicity in refractory hematologic malignancies. A prospective multicenter phase II trial was conducted to determine the efficacy of CloBu4 for patients proceeding directly to HCT with AML not in remission. Seventy-one patients (median age: 56 years) received CloBu4. At day 30 after HCT, 90% achieved morphologic remission. The incidence of non-relapse mortality and relapse at 2 years was 25% and 55%, respectively. The 2-year overall survival (OS) and event-free survival (EFS) were 26% and 20%, respectively. Patients entering HCT in PIF had significantly greater EFS than those in relapse (34% vs 8%; P<0.01). Multivariate analysis comparing CloBu4 with a contemporaneous cohort (Center for International Blood and Marrow Transplantation Research) of AML not in remission receiving other myeloablative conditioning (n=105) demonstrated similar OS (HR: 1.33, 95% confidence interval: 0.92-1.92; P=0.12). HCT with myeloablative CloBu4 is associated with high early response rates and may produce durable remissions in select patients with AML not in remission.

Indexed as

Hematopoietic Stem Cell TransplantationTransplantation ConditioningAdenine NucleotidesAdultAgedAllograftsArabinonucleosidesBusulfanClofarabineDisease-Free SurvivalFemaleHumansInduction ChemotherapyLeukemia, Myeloid, AcuteMaleMiddle AgedAdenine NucleotidesArabinonucleosidesBusulfanClofarabine

Identifiers

PMID27427921
PMCPMC5215562
OpenAlexW2492745064

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.